Sudden cardiac death after robbery: homicide or natural death? - Bottari G, Trotta S, Marzullo A, Meliota G, Ciccone MM, Solarino B.
Tako-Tsubo is one of a number of rare acquired cardiomyopathies that are characterized by left ventricular dyskinesia and symptomatology typical of acute myocardial infarction (AMI). The most important feature is that the clinical features are triggered by... (Source: SafetyLit)
Source: SafetyLit - September 21, 2020 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

What Drugs Cause Tardive Dyskinesia
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 2, 2020 Category: General Medicine Source Type: news

Parkinson's dyskinesia mechanism explained
(Scripps Research Institute) The mechanism underlying Parkinson's dyskinesia has been unknown, until now. An international collaboration led by Scripps Research, Florida has found a key cause, and with it, potentially, a new route to providing relief. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2020 Category: International Medicine & Public Health Source Type: news

Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS(R) (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
ONGENTYS, the First and Only Approved Once-Daily COMT Inhibitor, Decreases "Off" Time and Increases "On" Time Without Troublesome Dyskinesia When Added to Levodopa/Carbidopa in Patients with Parkinson's Disease Neurocrine Biosciences... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, ONGENTYS, opicapone, Parkinson's Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2020 Category: Pharmaceuticals Source Type: news

Image of the Day: Defective Cilia
Super-resolution imaging identifies abnormalities in the hair-like protrusions on a cell's surface and may help facilitate earlier detection of primary ciliary dyskinesia. (Source: The Scientist)
Source: The Scientist - April 7, 2020 Category: Science Tags: Image of the Day Source Type: news

What Are Some Risk Factors for Cerebral Palsy?
Discussion The term, cerebral palsy, or CP has gone through many iterations with the first description in 1861 by W.J. Little who described it as “The condition of spastic rigidity of the limbs of newborn children.” The most recent definition is from Rosenbaun et al. in 2007 which states it is “a group of permanent disorders of the development of movement and posture, causing activity limitation, that are attributed to non-progressive disturbances that occurred in the developing fetal or infant brain. The motor disorders of cerebral palsy are often accompanied by disturbances of sensation, perception, cog...
Source: PediatricEducation.org - March 9, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Promising drug could treat debilitating movement problems in people with Parkinson's
(Parkinson's UK) Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson's. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 1, 2020 Category: International Medicine & Public Health Source Type: news

Accidental Modopar poisoning in a two-year-old child: a case report - Lahlou A, Benlamkaddem S, Berdai MA, Harandou M.
Levodopa is a dopamine precursor and a mainstay treatment in the management of Parkinson's disease. Its side effects induce dyskinesia, nausea, vomiting, and orthostatic hypotension. Acute levodopa acute poisoning is uncommon, with only a few reported case... (Source: SafetyLit)
Source: SafetyLit - January 11, 2020 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Long-term Antibiotics Ease Symptoms of Genetic Lung Disorder Long-term Antibiotics Ease Symptoms of Genetic Lung Disorder
Azithromycin improves symptoms for patients with primary ciliary dyskinesia, but researchers caution that vigilance must be maintained to prevent antibiotic resistance.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 4, 2019 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

New Wearable Device Helps Detect Dyskinesia in Parkinson's New Wearable Device Helps Detect Dyskinesia in Parkinson's
The device can help physicians identify patients with motor fluctuations without spending long periods of time at the clinic, a new study suggests.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 9, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

A Wearable Device Is Changing the Way Clinicians Manage Parkinson & #039;s Patients
A recently published study in Functional Neurology suggests that using data from an FDA-cleared watch-like device called the Personal KinetiGraph (PKG) provides an objective and more effective approach to assessing motor fluctuations in patients with Parkinson's disease (PD) compared with patient-reported motor diaries. “Motor fluctuations, including 'wearing-off' and dyskinesia, are associated with increased disease severity and disability, and PD patients experience decreased quality of life as their response to medical therapy becomes less predictable,” said EchoÂ&nb...
Source: MDDI - August 2, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Source Type: news

Motor domain in psychotic disorders: the rebirth of a concept - Hirjak D, Kubera KM, Sambataro F, Wolf RC.
We were very pleased to read the excellent article by Swets et al. [1], who examined longitudinally for 3 years motor (akathisia, dyskinesia, parkinsonism and dystonia) and obsessive compulsive symptoms (OCS) in psychotic patients and individuals with i... (Source: SafetyLit)
Source: SafetyLit - June 29, 2019 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Two espressos a day cured boy, 11, who could barely walk due to Parkinson's-like shakes
An 11-year-old boy in Paris, France, was diagnosed with ADCY5-related dyskinesia, a movement disorder that caused him to involuntarily tremor and shake up to 30 times a day. (Source: the Mail online | Health)
Source: the Mail online | Health - June 10, 2019 Category: Consumer Health News Source Type: news

What Causes Temporomandibular Joint Problems?
Discussion The mandible normally grows in a symmetric downward and forward movement relative to the skull base. The condyle is the primary growth center. “The mandible is unique in that its 2 joints and growth centers function together as a single unit.” It is the last bone in the body to reach skeletal maturity. The mandible and its growth are important for maxillary growth and therefore many problems that affect the mandible affect the facial and skulls structures as well. These growth problems can be relatively insidious and therefore may need monitoring over longer periods of time such as patients with unde...
Source: PediatricEducation.org - May 27, 2019 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Should Wearables Target the & #039;Walking Well & #039; Before Going After a Medical Indication?
As recently as 2017, there was still more talk than action in the clinical wearables market and the majority of companies making wearable devices were pursuing health and wellness applications first, with plans to pursue a medical device indication after the consumer version of the product took off. In some cases that is still true, but a panel of experts speaking at BIOMEDevice Boston 2019 highlighted a new trend. One that might seem unexpected for those who have been following the wearables market for the past five years or longer. "I'm in the medical space, I'm used to dealing with CGMs [continuous glucose monitors...
Source: MDDI - May 20, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Digital Health Software Source Type: news

DUOGLOBE Interim Results: Intestinal Gel Cuts PD'Off' Time DUOGLOBE Interim Results: Intestinal Gel Cuts PD'Off' Time
Researchers release additional results looking at levodopa-carbidopa intestinal gel to help lessen motor fluctuations and dyskinesia in people with advanced Parkinson's disease.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 6, 2019 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Management of Antipsychotic-Induced Tardive Dyskinesia Management of Antipsychotic-Induced Tardive Dyskinesia
Newer generation antipsychotics have reduced, but not eliminated, the risk of antipsychotic-induced tardive dyskinesia. What are the best management options for this debilitating adverse effect?Current Opinion in Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 22, 2019 Category: Consumer Health News Tags: Psychiatry Journal Article Source Type: news

Explaining the Renewed Interest in Tardive Dyskinesia Explaining the Renewed Interest in Tardive Dyskinesia
According to Dr Jeffrey Lieberman, it's not science but marketing that's driving the rise in TD coverage.Medscape Psychiatry (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 25, 2019 Category: Consumer Health News Tags: Psychiatry Commentary Source Type: news

Paroxysmal kinesigenic dyskinesia presented following concussion - Cottrill N, McCully B, Payne M.
[Abstract unavailable] Language: en... (Source: SafetyLit)
Source: SafetyLit - December 25, 2018 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Adaptive Deep-Brain Stimulation Promising for Parkinson's Adaptive Deep-Brain Stimulation Promising for Parkinson's
Researchers test a DBS device in development that automatically senses and adjusts delivery of electrical stimulation, aiming to avoid dyskinesia and other side effects of current technology.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 12, 2018 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Report: Apple update improves Watch ’ s ability to track movement disorders
Apple (NSDQ:AAPL) is upping its diagnostic game with the Apple Watch yet again, adding the ability to more accurately detect tremors for individuals with Parkinson’s Disease, according to a CNBC report. The company is updating the bio-sensor laden smartwatch to make it easier for researchers to differentiate between random movement and the shakes and dyskinesia experienced by Parkinson’s patients while they’re under treatment from medication, according to the report. The announcement came last week at Apple’s WWDC developer conference, CNBC reports. The updated movement disorder API will allow ...
Source: Mass Device - June 12, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News mHealth (Mobile Health) Patient Monitoring Apple Source Type: news

Anticholinergic medication for antipsychotic-induced tardive dyskinesia.
Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side-effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia. To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadr...
Source: Current Awareness Service for Health (CASH) - May 25, 2018 Category: Consumer Health News Source Type: news

Benzodiazepines for antipsychotic-induced tardive dyskinesia
Tardive dyskinesia (TD) is a disfiguring movement disorder, often of the orofacial region, frequently caused by using antipsychotic drugs. A wide range of strategies have been used to help manage TD, and for those who are unable to have their antipsychotic medication stopped or substantially changed, the benzodiazepine group of drugs have been suggested as a useful adjunctive treatment. However, benzodiazepines are very addictive. To determine the effects of benzodiazepines for antipsychotic-induced tardive dyskinesia in people with schizophrenia, schizoaffective disorder, or other chronic mental illnesses. (Source: Curr...
Source: Current Awareness Service for Health (CASH) - May 25, 2018 Category: Consumer Health News Source Type: news

Insightec seeks Parkinson ’ s indication in Japan for Exablate Neuro
Insightec said this week it submitted an application for pre-market approval to the Japanese Pharmaceuticals and Medical Devices Agency seeking an indication for its Exablate Neuro to treat advanced Parkinson’s Disease in patients suffering from mobility, rigidity or dyskinesia. The Israel-based company’s Exablate Neuro device uses high-intensity, focused ultrasound to thermally ablate targeted tissue, guided by continuous magnetic resonance imaging; the procedure can be performed non-invasively through an intact skull. “Insightec is committed to supporting research that extends the applica...
Source: Mass Device - May 18, 2018 Category: Medical Devices Authors: Fink Densford Tags: Neurological Regulatory/Compliance Ultrasound INSIGHTEC Source Type: news

Boston Scientific touts 1-year data on Vercise DBS in Parkinson ’ s
This study meets a new level of rigor in evaluating the effectiveness of a DBS system,” coordinating principal investigator Dr. Jerrold Vitek, of the University of Minnesota Medical School, said in prepared remarks. “The double-blind design gives us confidence that the improvements in patients on time with good symptom control, as evaluated by the diary data, are an objective measure of the outcomes and suggests patients will benefit from the Vercise System.” Vercise won CE Mark approval in the European Union to treat essential tremor in 2014. FDA approval to treat Parkinson’s followed las...
Source: Mass Device - April 24, 2018 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Neuromodulation/Neurostimulation Boston Scientific Parkinson's disease Source Type: news

Positive Long-term Results for Tardive Dyskinesia Drug Positive Long-term Results for Tardive Dyskinesia Drug
Long-term efficacy and safety/tolerability outcomes are positive in older patients with tardive dyskinesia treated with valbenazine, according to pooled analyses from several phase 3 trials.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 3, 2018 Category: Consumer Health News Tags: Psychiatry News Source Type: news

New study explains how your brain helps you learn new skills
(Gladstone Institutes) Researchers from the Gladstone Institutes uncovered how a special type of neuron improves the efficiency of procedural learning. They initially wanted to show how the specialized brain cells, called fast-spiking interneurons, cause movement disorders, such as Tourette's syndrome, dystonia, and dyskinesia. As it turns out, that isn't the case. But their work led them to an even greater discovery. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 8, 2018 Category: International Medicine & Public Health Source Type: news

Non-profit to accelerate development of potential new Parkinson's drug
(Parkinson's UK) UK charity, Parkinson's UK is partnering with US biotech Neurolixis in a $1 million deal to accelerate the development of a potential cure for dyskinesia -- a severe side effect of common Parkinson's medication. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 24, 2018 Category: International Medicine & Public Health Source Type: news

ICER issues final report on VMAT2 inhibitors for tardive dyskinesia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2018 Category: Drugs & Pharmacology Source Type: news

Medical News Today: All you need to know about akinesia
A look at akinesia, a condition where a person cannot move their muscles as they wish. Included is detail on the difference between akinesia and dyskinesia (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 10, 2017 Category: Consumer Health News Tags: Parkinson's Disease Source Type: news

All you need to know about akinesia
A look at akinesia, a condition where a person cannot move their muscles as they wish. Included is detail on the difference between akinesia and dyskinesia (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - December 10, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news

What is the definition of akinesia?
A look at akinesia, a condition where a person cannot move their muscles as they wish. Included is detail on the difference between akinesia and dyskinesia (Source: Parkinson's Disease News From Medical News Today)
Source: Parkinson's Disease News From Medical News Today - December 10, 2017 Category: Neurology Tags: Parkinson's Disease Source Type: news

Medical News Today: Tardive dyskinesia: What you need to know
Tardive dyskinesia is a side effect of some drugs that causes unintended muscle movements, usually in the face. Learn about which medications cause it. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 29, 2017 Category: Consumer Health News Tags: Schizophrenia Source Type: news

Motor system pathology in psychosis - Walther S, Mittal VA.
PURPOSE OF REVIEW: Motor abnormalities are an intrinsic feature of psychosis. Neurological soft signs, Parkinsonism, dyskinesia, and other motor phenomena are frequently observed in subjects at clinical or genetic risk for psychosis as well as first-episod... (Source: SafetyLit)
Source: SafetyLit - November 6, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

FDA approves pivotal trial for Insightec ’ s Exablate Neuro in Parkinson ’ s
Insightec said today that it won FDA approval for a pivotal trial of its Exablate Neuro device in treating refractory Parkinson’s disease. Haifa, Israel-based Insightec said the the study will evaluate using Exablate Neuro’s MR-guided focused ultrasound to ablate portions of the globus pallidus in the brain, which helps regulate voluntary movement. The trial, led by principal investigator Dr. Howard Eisenberg of the University of Maryland, aims to treat dyskinesia in patients with advanced Parkinson’s who have not responded to medication. “Insightec remains committed to advancing research to ex...
Source: Mass Device - October 25, 2017 Category: Medical Devices Authors: Brad Perriello Tags: Clinical Trials Food & Drug Administration (FDA) Imaging Radiosurgery INSIGHTEC Source Type: news

Medical News Today: What you need to know about dyskinesia
We look at dyskinesia, including the main symptoms and treatment options. Learn more about this condition that results in involuntary movements here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 19, 2017 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news

Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks INBRACE™ program offers patients access to treatment and patient assistance SAN DIEGO, Oct. 5, 2017 -- (Healthcare ... Biopharmaceuticals, Neurology, FDA Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 5, 2017 Category: Pharmaceuticals Source Type: news

ICER publishes draft report on 3  tardive dyskinesia therapies
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2017 Category: Drugs & Pharmacology Source Type: news

9 Brand New Drugs for Primary Care
COPD … nasal polyps.. gout …. dyskinesia in Parkinson Disease: here’s a brief look at new drugs for these and other disorders coming your way. (Source: ConsultantLive)
Source: ConsultantLive - September 28, 2017 Category: Internal Medicine Authors: Susan Kweskin Tags: COPD Gout Source Type: news

Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia
Antipsychotic medication can cause tardive dyskinesia (TD) – late-onset, involuntary, repetitive movements, often involving the face and tongue. TD occurs in> 20% of adults taking antipsychotic medication (first-generation antipsychotics for> 3 months), with this proportion increasing by 5% per year among those who continue to use these drugs. The incidence of TD among those taking newer antipsychotics is not different from the rate in people who have used older-generation drugs in moderate doses. Studies of TD have previously been found to be limited, with no treatment approach shown to be effective. To summ...
Source: Current Awareness Service for Health (CASH) - September 25, 2017 Category: Consumer Health News Source Type: news

Second Tardive Dyskinesia Drug Okayed
(MedPage Today) -- Deutetrabenazine (Austedo) joins valbenazine (Ingrezza) in TD indication (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - August 31, 2017 Category: Neurology Source Type: news

FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia FDA OKs Deutetrabenazine (Austedo) for Tardive Dyskinesia
The drug was also approved for chorea associated with Huntington's disease earlier in this year.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Teva Announces FDA Approval of Austedo (deutetrabenazine) Tablets for the Treatment of Tardive Dyskinesia in Adults
JERUSALEM--(BUSINESS WIRE) August 30, 2017 --Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved Austedo (deutetrabenazine) tablets for the treatment of tardive... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Okays Parkinson's Dyskinesia Drug
(MedPage Today) -- Immediate-release version already used off-label for condition (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 25, 2017 Category: American Health Source Type: news

FDA Clears First Drug for Parkinson's Dyskinesia FDA Clears First Drug for Parkinson's Dyskinesia
The FDA has approved the first drug for treatment of dyskinesia in patients with Parkinson's disease dyskinesia, fulfilling an"unmet need" in PD management, experts say.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

FDA Approves Gocovri (amantadine) for the Treatment of Dyskinesia in Parkinson's Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved Gocovri (amantadine) extended release capsules (previously ADS-5102) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 25, 2017 Category: Drugs & Pharmacology Source Type: news

Adamas Pharma secures approval for Parkinson's dyskinesia drug
(Reuters) - The U.S. Food and Drug Administration (FDA) said it had approved Adamas Pharmaceuticals Inc's treatment for a side effect caused by a commonly prescribed Parkinson's drug, sending the shares of the drugmaker soaring in after-market trading. (Source: Reuters: Health)
Source: Reuters: Health - August 24, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes drug may be helpful for Parkinson's disease
Conclusion This research shows some interesting early findings, though the magnitude of effect was very small compared to the improvements in symptoms with current dopaminergic drugs. The study was well conducted but did have some limitations: The number of people taking part was quite small. This may have meant it was hard to detect any other benefits or harms of taking the drug other than the effects on motor scores. The period of time people were given the drug and followed up meant that longer-term effects could not be measured. The benefit of the drug observed so far might not be big enough to make a difference ...
Source: NHS News Feed - August 4, 2017 Category: Consumer Health News Tags: Neurology Source Type: news

Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use Drug Eases Tardive Dyskinesia Linked to Antipsychotic Use
Deutetrabenazine significantly reduced abnormal involuntary movements in patients with tardive dyskinesia caused by antipsychotic drugs in a phase 3 study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 5, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news